

Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics

Fatemeh Movahedi ^a, Li Li ^{*a}, Zhi Ping Xu ^{*a,b}

^a Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia

^b Institute of Biomedical Health Technology and Engineering and Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen 518107, China

ABSTRACT

Cancer chemotherapy is generally associated with many severe adverse effects. Many cancer studies are currently focused on repurposing conventional non-toxic anti-parasite drugs for cancer treatment. Since cancer cells and parasites have many features in common, some anti-parasite drugs such as benzimidazoles have been recently found to possess the anti-cancer activity. Benzimidazoles act against cancer by inhibiting tubulin polymerization, inducing cancer cell apoptosis, arresting cell cycle and over-generating reactive oxygen specimen. In this review, we summarize the anticancer features of these drugs in recent investigations, lead to reconsideration of benzimidazoles as a family of anti-cancer chemotherapeutics with non-toxicity or low toxicity to the normal cells and tissues. We particularly highlight the recent progresses using nanoformulations for enhanced cancer therapy and provide our prospects in the future research.

KEYWORDS

Anti-parasite; Benzimidazoles; Anti-cancer activity; Inhibition of tubulin polymerization; Selective chemotherapeutics

*Corresponding authors: Zhiping Xu, Li Li
E-mail addresses: gordonxu@uq.edu.au; lli2@uq.edu.au

1. Introduction

Conventional chemotherapeutics are normally non-selective. These therapeutic agents not only kill cancer cells but also damage healthy tissues and cells, causing adverse effects [1] and influencing patients' quality of life [2]. For this reason, there is a great motivation to repurpose conventional anti-pathogen drugs with a long-term safety history for cancer chemotherapy. The benzimidazole family is one of such safe drugs.

Benzimidazoles are heterocyclic organic compounds, consisting of imidazole and benzene (as illustrated in **Figure 1**) with a high anti-helminth efficacy and a low level of toxicity to healthy cells [3, 4]. Apart from the high anti-helminth activity, benzimidazoles have been also found to possess anti-fungal [4], anti-bacterial [5], anti-viral [6] and anti-inflammatory activity [7]. Due to extensive similarities between parasites and cancer cells [8], benzimidazoles have also shown some anti-cancer activity, as confirmed in many studies [9]. Moreover, benzimidazole drugs are reported to enhance the efficacy in combination with other treatments such as conventional chemotherapy [10] and radiation therapy [11]. Interestingly, some benzimidazole drugs induce apoptosis of drug-resistant cancer cell lines [12] [13]. More importantly, benzimidazole drugs kill cancer cells in a selective way [14], i.e. *via* targeting tubulin polymerization dominantly in rapidly dividing cells such as parasites and cancer cells [15], leaving healthy cells being not much affected.




Figure 1. Chemical structure of benzimidazole drugs (albendazole and mebendazole) as heterocyclic organic compounds, consisting of imidazole and benzene, as well as other functional groups [126].

Although benzimidazole drugs have shown promise for cancer therapy, their low water solubility presents a significant challenge for their clinical application and therapeutic outcomes [16]. To overcome this limitation, nanoformulating benzimidazole drugs has emerged as a viable approach to increase their solubility and improve their efficacy in cancer therapy.

In this review, we aim to summarize the anti-parasite and anticancer features of benzimidazole drugs and their mechanisms of action. We further highlight the superior potentials of benzimidazoles such as safety and effectiveness on resistant cancer cells along with the limitation to their clinical applications, and then present the recent progresses using their nanoformulations for enhanced cancer therapy in combination with other drugs or treatment modes.

2. Anti-parasite performance of safe benzimidazole drugs

Benzimidazole drugs have widely been used as anti-helminth agents in both human and livestock since the 1960s [17]. These drugs have rapidly become more popular than previous medications due to superiority in terms of efficacy, toxicity and application [18]. For instance, benzimidazoles have high anti-parasitic effect on some protozoa, cestodes (tapeworms), trematodes (flukes) and nematodes (roundworms) [19], as summarized in **Table 1**. Interestingly, benzimidazole derivatives, triclabendazole and praziquantel, are considered as the main treatments for trematoda [20]. However, praziquantel had no efficacy while triclabendazole was highly effective

for some trematoda such as *fasciolias* [21].

Table 1. The antihelminth effect of benzimidazole drugs

Helminth type	Helminth sub-type	Benzimidazole drug	Outcome	Ref.
Protozoa	<i>Giardia lamblia</i> , <i>Trichomonas vaginalis</i> and microsporidia in AIDS patients	Fenbendazole, flubendazole, mebendazole	Half inhibitory concentration (IC ₅₀) of 0.005 to 0.16 µg/ml	[26, 28]
	<i>Tritrichomonas foetus</i>	Albendazole, mebendazole	IC ₅₀ of 2.3-9.4 µM	[17]
	<i>Giardia duodenalis</i>	Albendazole, mebendazole and fenbendazole	IC ₅₀ of 0.19-0.3 µM	[27]
Cestodes	<i>Moniezia benedeni</i>	Fenbendazole	Effective in concentration of 1-15 µM	[23]
		Mebendazole	Diminished ATP synthesis after 30 minutes exposure	[24]
Trematoda	Lung flukes (<i>Paragonimus</i>)	Triclabendazole	100% cure rate with two doses of 50-75 mg/kg	[127]
	Opisthorchiasis	Mebendazole	100% egg reduction rate and 94% cure rate by 30 mg/kg/day	[128]
	Liver flukes (<i>Fasciola</i>)	Triclabendazole	100% egg reduction rate and 86% cure rate by 5 mg/kg	[129]
Nematodes	<i>Ascaridia galli</i>	Fenbendazole, parabendazole, mebendazole, oxfenbendazole, thiabendazole	IC ₅₀ of 4.5-8 µM	[25]
	<i>Oesophagostomum dentatum</i>	Fenbendazole	99.9% cure rate by 3×3 mg/kg fenbendazole	[130]
	<i>Oesophagostomum quadrispinulatum</i>		100% cure rate by 3×3 mg/kg fenbendazole	
	<i>Ascaris sum</i>		92.4% cure rate by 3×3 mg/kg fenbendazole	
	<i>Trichuris suis</i>		66% cure rate by 3×3 mg/kg fenbendazole	
	<i>Hyostrongylus rubidus</i>		99.9% cure rate by 3×3 mg/kg fenbendazole	

Benzimidazole drugs also have some activity against cestodes [22]. For example, fenbendazole proved efficacy for *Moniezia benedeni* cestode in the concentration of 1-15 µM [23] and mebendazole inhibited ATP synthesis in *Moniezia expansa* after 30 min exposure [24]. In general, many members of benzimidazole family drugs, including fenbendazole, parabendazole, mebendazole, oxfenbendazole and thiabendazole, have demonstrated effectiveness against nematodes with the IC₅₀ value of 4.5-8 µM [25].

In addition to intestinal helminths, protozoa such as *Giardia lamblia*, *Trichomonas vaginalis* and even microsporidia in AIDS patients, proved high susceptibility to benzimidazole derivatives such as fenbendazole, flubendazole and mebendazole, with the IC₅₀ value being 0.005-0.16 µg/ml [26] (nearly 0.02-0.6 µM). Similarly, *Tritrichomonas foetus* protozoa were affected by albendazole and mebendazole with the IC₅₀ of 2.3-9.4 µM [17]. Albendazole, mebendazole and fenbendazole demonstrated the highest activity against protozoa among benzimidazole drugs [27], being 30-50 times more effective on *Giardia lamblia* than the non-benzimidazole drug, metronidazole [28].

Benzimidazole drugs are considered as non-toxic anti-helminth agents in human and livestock [29, 30]. Acute toxicities are rarely reported for these drugs [29, 31]. Neither chronic adverse effects in dogs and rats treated with very high dosages, nor irritation, carcinogenicity or teratogenicity in treated rats and rabbits have been observed [32]. The reported adverse effects mainly include abdominal pain or other gastrointestinal symptoms in 6-12% treated patients, headache in 2-3%, hair loss in 2%, and symptoms such as vertigo, thrombocytopenia, sleepiness, fever and fatigue in less than 1% treated patients [33, 34]. The safety of benzimidazole drugs mainly comes from the selective mode of actions on rapidly proliferating cells [35] through specifically targeting tubulin polymerization [36], which enables benzimidazole drugs to possess anti-cancer activity in a very safe way as well.

3. Common features of cancer cells and parasites suit actions of benzimidazole drugs

Parasites and cancer cells have many common features, as summarized in Table 2. In general, they are both resistant to apoptosis and capable of unlimited proliferation in human and livestock [37]. Both are capable of changing the expression of antigens exposed to the immune system of the host, masking the membrane components to survive in adverse conditions and secreting enzymes such as protease for the facilitated invasion to the host tissue [8]. Finally, both parasites and cancer cells are able to guide many innate immune cells such as monocytes to form a proper microenvironment, allowing them to survive and proliferate well, evading other tissues and escaping from the immune system [38].

Table 2. Common properties of cancer cell and parasite

Common features of parasites and cancer cells	Ref.
Resistance to apoptosis	[36]
The capability of unlimited proliferation in the host	[36]
Changing the expression of antigens exposed to the host immune system	[7]
Masking components on the cell membrane for survival in adverse conditions	[7]
Secretion of enzymes such as protease to facilitate the invasion	[7]
Guiding innate immune cells such as monocytes to allow them to evade and escape from the immune system	[37]

Due to such similar functions, many anti-cancer drugs such as ivermectin [39], artemisinin [40] and histone deacetylase inhibitors [41] have been utilized for parasite treatment. On the other hand, some anti-parasite drugs such as niclosamide [42], mefloquine [43] and manzamine A [44] have been employed for cancer chemotherapy. Considering the safety and efficacy of benzimidazole drugs for parasite treatment for many years, these drugs are also good candidates for being repurposed as anticancer drugs.

The mechanisms of biological activity of benzimidazole drugs against parasites and cancer cells are schematically summarized in **Figure 2**, including two major mechanical actions. The first action is their anti-mitotic activity, stemming from the inhibition of tubulin polymerization through binding to tubulin sites of rapidly dividing cells [35]. Suppressing tubulin polymerization results in the disruption of mitotic spindle formation [45] and arrests cell cycle in the mitotic stage [46]. Thus, the disassembly of microtubules reduced the expression of vascular endothelial growth factor receptor-2 (VEGFR2) [47] and the suppression of VEGFR2 leads to the inhibition of angiogenesis, cell migration and invasion [48]. The alteration of the microtubule network has also affected the activity of hypoxia-inducible factor-1 α protein [49] and shifted the balance of anti-apoptotic proteins such as Bcl-2 and apoptosis induction as a result [50].




Figure 2. The schematic mechanisms of actions of benzimidazole drugs.

Secondly, benzimidazole drugs are also able to disrupt cell metabolic processes by inducing the oxidative stress [51] and reducing the level of available adenosine triphosphate (ATP) [52]. Such a metabolic disruption may result in the inhibition of glucose uptake [53] and activity of key enzymes such as cytoplasmic and mitochondria malate dehydrogenase [54], phosphoenolpyruvate [55], fumarate reductase [56], protein kinase [57] and cysteine protease [58].

Therefore, the specific mechanisms of action of benzimidazole drugs selectively induce apoptosis of rapidly proliferating parasites and cancer cells, which largely reduces the negative influences on the healthy cells. This

feature identifies these drugs as selective safe anti-cancer chemotherapeutics.

4. Selective anti-cancer effect of benzimidazole family drugs

As listed in **Table 3**, many benzimidazole family drugs such as albendazole, fenbendazole, mebendazole, flubendazole, pantoprazole, oxibendazole, oxfendazole, rabeprazole, MBIC and IODVA1, have shown anti-cancer effect on a wide range of cancer cells.

Table 3. A summary of reported anticancer activities of benzimidazole drugs

Cancer type	Drug	Cell line	Dosage	Outcome	Ref.
Breast cancer	IODVA1 (guanidino benzimidazole derivative)	MDA-MB-231	(IP) injection of 3.5 mg/kg -three times per week	Diminishing $\geq 50\%$ of tumour volume-significant increase in apoptosis induction	[131]
	Flubendazole	MDA-MB-231, Hs578T BT-549 and 4T1-Luc	10 mg/kg/day, every other day	Anti-metastatic effects through STAT3 inhibition	[88]
	Albendazole	MCF-7	1-100 μM	Increasing oxidative biomarkers, GSH depletion, triggering apoptosis, enhancing the expression of Bax/Bcl-xL, p53 and Bax	[59]
Hepatocellular carcinoma	MBIC	HepG2 and Huh7	Three times of 25 mg/kg intraperitoneal injections per week for 4 consecutive weeks	Apoptosis induction through the activation of caspase-3, reduced cell migration and invasion, ROS generation and activation of c-Jun-N-terminal kinase (JNK)	[64]
Gastric cancer	Pantoprazole	HGC27	orally administered daily by gavage at a dose of 75 mg/kg-4 weeks	Repression of telomerase reverse transcriptase (TERT) expression, metastasis inhibition	[89]
	Rabeprazole	AGS, KATO III, MKN-28 and MKN-45	-	Inhibiting the phosphorylation of ERK $\frac{1}{2}$	[61]
	Mebendazole	ACP-02, ACP-03 and AGP-01	0.15–20 μM	Significant reduction of invasion, migration and MMP-2 activity	[62]

Non- small cell lung cancer	Oxfendazole	A549, H460, H1299, H1650 and H1975	5-20 μ M	Decreased expression of c- Src, upregulation of p53 and p21	[63]
	Mebendazole	H460, A549, H1299, and WI-38	1 mg oral	Induction of abnormal spindle formation, enhanced tubulin depolymerisation, strong antitumour effect, reducing lung colonies	[68]
Ovarian cancer	Albendazole	SKOV3 and OVCAR3	0.5-10 mg/kg	Suppression of tumour growth, ascite formation, VEGF and SPARC expression	[71]
Prostate cancer	Oxibendazole	22Rv1 and PC-3	25 mg/kg/day	50% tumour size reduction, increased level of microRNA-204 and p53	[66]
Fibrosarcoma	Mebendazole	BHK-21/C13	460 mg/kg via gastric tube	Enhanced tumour necrosis, diminished vasculature penetration and tumour mitosis	[69]
colorectal cancer	Flubendazole	HCT116, RKO, SW480	10 mg/kg or 30 mg/kg by intraperitoneal (i.p.) injection every other day	Inhibition of STAT3 genes transcription, P-mTOR, P62, BCL2 and upregulation of LC3-I/II and Beclin1 genes	[64]
Neuroblastoma	Flubendazole	primary neuroblastoma cells	50-800 nM	P53-mediated apoptosis induction	[30]
Hepatocellular Carcinoma	Albendazole	HepG2, Hep3B and SKHEP-1	300 mg/kg per day for 20 days - Oral	Cell cycle arrest at G0-G1 or G2-M depending on drug dosage, tumour growth suppression	[67]
Non-small cell lung cancer	Mebendazole	A549 and WI38	200-800 μ g/day-Oral administration	75% tumour size reduction, reduced number and size of colonies in lung, reduced vessel densities	[70]
	Fenbendazole	A549	1 mg - Oral	Mitochondrial translocation of p53, inhibition of glucose uptake and glycolytic enzymes, tumour size reduction	[60]
Brain cancer	Mebendazole	GL261	50-100 mg/kg - Oral	Significant enhancement of survival time even compared with vincristine	[132]

In a nutshell, these drugs effectively inhibit tumor proliferation and growth through (1) reducing GSH [59], glycolytic enzymes, and glucose uptake [60]; (2) decreasing phosphorylation of ERK1/2 [61]; (3) mitigating the activity of matrix metalloproteinases 2 (MMP-2) [62] and expression of c-Src [63], P-mTOR, P62, Bcl-2 and STAT3 gene transcription [64]; (4) increasing the level of Bax/Bcl-xL [59], p21[63], p53 [59], caspase 3 [65], LC3-I/II and Beclin1 genes [64], microRNA-204 [66], oxidative biomarkers and ROS; (5) activating c-Jun-N-terminal kinase (JNK) [64]; and (6) arresting cell cycle in G0-G1 or G2-M phase [67] and triggering apoptosis.

These benzimidazole drugs have also proved high efficacy in inducing abnormal spindle formation, increasing tubulin depolymerization [68], inhibiting vasculature penetration [69] and diminishing vessels in tumor tissues [70], suppressing VEGF and SPARC expression [71], as well as decreasing colony [70] and ascites formation [71].

A recent study has examined the impact of a wide range of benzimidazole drugs, including flubendazole, parbendazole, oxibendazole, mebendazole, albendazole, and fenbendazole, on tumor cells derived from paraganglioma, pancreatic, and colorectal cancer [72]. Many of these drugs demonstrated IC50 values within the low micromolar or nanomolar range. *In silico* analysis indicated no interaction between those drugs and P-gp permeability glycoprotein that plays a pivotal role in drug efflux in tumors. The results also confirmed moderate to good oral bioavailability. Significantly, target prediction analysis of benzimidazole drugs revealed some cancer-related molecular targets for fenbendazole and mebendazole with high probability scores.

In efforts to achieve higher efficacy with low drug dosages, many new benzimidazole derivatives have been developed for the treatment of cancers such as colon cancer [73], breast cancer [74], lung cancer [75], chondrosarcoma [76] and leukemia [77]. Many new derivatives are screened and effective against a very broad range of cancers [78, 79]. Furthermore, new benzimidazole derivatives have demonstrated high capability for overcoming drug resistance. For instance, a benzimidazole derivative with a pyrrolidine chain significantly reduced the proliferation and migration of sorafenib-resistant hepatocellular carcinoma cells [80]. Similarly, benzoxazole-based zinc and copper complexes showed remarkably increased apoptosis induction in multidrug resistant L5178Y mouse T-lymphoma compared to non-complex ones [81].

Benzimidazole drugs' side effects are rare and mild. Recent studies have further confirmed the selective mode of actions of benzimidazole drugs against cancer cells. For instance, albendazole inhibited ovarian tumor growth but showed no toxicity to HOSE normal ovary cells [71]. Mebendazole did not show any toxicity to HUVEC cells while it was highly toxic to lung cancer cells [70]. Recently, our group has also shown that 4 benzimidazole drugs induced significant anti-cancer efficacy on B16F0 melanoma cells, but no obvious toxicity to HEK293T healthy cells [82]. Such a distinct mode of action comes from targeting tubulin polymerization overexpressed in cancer cells [83]. Furthermore, cancer cells are more susceptible to oxidative stress [84] and benzimidazole drugs are recognized as ROS generators [85, 86].

5. Inhibition of metastatic cancer cells, cancer stem cells, and drug-resistant cancer cells

Interestingly, benzimidazole drugs exhibit anti-metastatic effect through inhibiting cell migration and invasion [65]. As an example, mebendazole suppressed metastatic potential of anaplastic 8505c cells and prevented lung metastasis in advanced thyroid cancer mouse model [87]. Such inhibitions stems from reducing the activity of matrix metalloproteinases 2 (MMP-2) [62] and repression of signal transducer and activator of transcription 3 (STAT3) [88], which is considered as the key regulator of cancer metastasis by transducing the signals from cell surface receptors to the nucleus. Benzimidazole drugs also suppress telomerase reverse transcriptase (TERT) expression [89], whose activation is associated with metastasis [90].

It is well known that most of chemotherapeutics kill bulk cancer cells but not cancer stem cells, where cancer

stem cells are responsible for tumor recurrence [91]. Benzimidazole drugs are potent in targeting cancer stem cells and preventing tumor recurrence. For instance, mebendazole significantly suppressed tubulin polymerization in temozolomide-resistant stem-like glioblastoma cells [92]. It is also reported that mebendazole depleted triple-negative breast cancer stem cells [93].

Benzimidazole drugs are also found to prevent the radiation-induced transformation of cancer cells into radiation-resistant cells, and furthermore sensitize some drug-resistant cells. Many studies have reported the susceptibility of taxane-resistant cancer cells to benzimidazole drugs, especially albendazole [13, 94]. The superiority of albendazole to taxane drugs comes from targeting tubulin polymerization [95]. Albendazole also demonstrated higher efficacy in reducing the level of Bcl-2 antiapoptotic protein, whose expression is elevated in drug-resistant cells [94]. Flubendazole showed inhibitory activity on vinblastine-resistant leukemia cells in spite of glycoprotein overexpression [12]. Temozolomide-resistant glioblastoma cells also showed susceptibility to mebendazole [92]. Therefore, benzimidazole drugs own great potentials for the treatment of drug-resistant cancer cells. Note that benzimidazole treatment may also result in tubulin mutation and subsequent resistance [92].

Due to the successful outcomes in *in vitro* and *in vivo* studies, clinical trials are ongoing for cancer therapy with benzimidazole drugs. For example, clinical study of mebendazole as adjuvant treatment for colon cancer is in Phase 3 (NCT03925662) and mebendazole in combination with other antiprotozoal agents including albendazole for neoplasm therapy is in Phase 2 (NCT02366884). Three Phase 1 clinical trials are also ongoing for brain tumors (NCT02644291, NCT01729260, NCT0183787862). Letrozole and omeprazole are other benzimidazole drugs in Phase 2 clinical trials before the surgery treatment (to stop the growth of tumor cells and then surgery to remove the tumor) or adjuvant chemotherapy for breast cancer (NCT03774472 and NCT02595372).

6. Nanoformulation for enhanced anti-cancer effect

In spite of the broad spectrum of applications in cancer therapy, the low water solubility of benzimidazole drugs impedes their clinical applications and therapeutic outcomes [16]. Chemical modification of benzimidazoles generates many new derivatives with higher water solubility [16, 96]. More promisingly, nanoformulating benzimidazole drugs that are safely used for many years has emerged as a feasible approach to increase the bioavailability with extra advantages, including:

- i. Extending the lifetime of benzimidazole drugs in blood circulation: Kupffer cells are specialized macrophages that play a crucial role in defending against foreign particles, bacteria, and other debris that enter the bloodstream [97]. However, the unique physicochemical properties of nanoparticles present a challenge to these cells due to their small size. Smaller nanoparticles, particularly those with a neutral or slightly negative charge, are less likely to be recognized and phagocytosed by Kupffer cells and cleared by the immune system [98], resulting in a longer circulation time in the bloodstream. This extended circulation time allows nanoparticles to accumulate at the tumor site with greater specificity and in higher quantity. This "stealth effect" of nanoparticles is dependent on several factors, such as their size [99], shape [100], and surface chemistry [101].

- ii. Enhanced permeability and retention (EPR) at the tumor site: EPR is a phenomenon observed in solid tumors where nanoparticles can passively accumulate at the tumor site. The leaky blood vessels and impaired lymphatic drainage within the tumor microenvironment allow nanoparticles to accumulate selectively at the tumor site [102]. This accumulation can increase the efficacy of anti-cancer drugs while reduce systemic exposure to healthy tissues, thus improving the therapeutic index of drugs [103].
- iii. Potential stimuli-responsive release: Stimuli-responsive nanoparticles can be designed to release drugs in response to specific stimulators within the tumor microenvironment, allowing for the targeted delivery of drugs to cancer cells while minimizing the exposure of healthy tissues to high drug concentrations [104]. For instance, lipid-coated calcium phosphate (LCP) nanoparticles released albendazole at pH 6-6.5, which is supposed to be similar to that in the tumor microenvironment while keeping the cargo intact at pH 7.4 [105].
- iv. Potential target delivery: Nanoparticles can have targeting capability by functionalizing their surface with specific molecules that can selectively bind to cancer cells. Nanoparticles can circulate until they encounter the target cancer cells, where they can bind to the receptors on the cell surface and enter the cells via endocytosis. This allows the nanoparticles to deliver their therapeutic payload directly to the cancer cells, while minimize exposure to healthy tissues and reduce systemic toxicity. Folic acid has widely been used as a targeting moiety for the targeted delivery of benzimidazole drugs to cancer cells due to overexpression of the folate receptors on cancer cells [106]. As an example, the use of folic acid-targeted chitosan nanoparticles for the delivery of mebendazole in the treatment of murine triple-negative breast cancer has been shown to be particularly effective by significantly reducing tumor size and extending the survival time of mice with triple-negative breast cancers [107]. Similarly, utilizing folate-conjugated bovine serum albumin (BSA) for co-delivery of albendazole and nanosilver simultaneously inhibited the energy metabolism of tumor cells, demonstrating superior anti-tumor efficacy compared to other nanoparticles lacking folic acid modification [108].

Numerous nanoformulations of benzimidazole drugs have been developed in light of the aforementioned benefits. Some of the formulations, such as liposome for fenbendazole [109] and compritol [110], silver nanoparticles [111] for mebendazole, graphite-diamond nanoparticles for thiabendazole [112], polybutyrcyanocrylate [113], solid lipid nanoparticles for albendazole [114], and methoxy polyethylene glycol-polycaprolactone nanoparticles for flubendazole [115], have already been developed for parasite therapy. Of course, these similar nanoformulations can also be explored for cancer therapy. An example is incorporating albendazole into chitosan-coated PLGA nanoparticles (260–480 nm), which elevated albendazole release to 200-fold compared to untreated albendazole, resulting in superior mucoadhesion and cytotoxicity [116]. Some nanoformulations of benzimidazole drugs have also been specifically studied for cancer therapy. As illustrated in **Figure 3**, albumin nanoparticles in the size of 7-10 nm were promising carriers of albendazole, reducing tumor size at a very low drug dosage while 200 nm albumin nanoparticles were less effective [117]. In addition to confirming improved anti-cancer efficacy of albendazole in nanoparticle forms, these results confirm the importance of the nanoparticle size to the treatment efficiency. The uptake of nanoparticles plays a pivotal role to increasing the treatment efficiency and smaller nanoparticles are more likely to be taken up by tumor cells [117].




Figure 3. The average tumor weight (A), average body weight (B), and body circumference (C) in OVCAR3-bearing mice treated with free albendazole or albumin nanoparticle formulation of albendazole in 10 or 200 nm nanoparticles [117].




Figure 4. Apoptosis induction in B16F0 cells (A), ROS generation in B16F0 cells (B), ROS generation in HEK293T cells (C), relative Bcl-2 expression in B16F0 cells (D), and relative Bcl-2 expression in HEK293T cells (E) treated with free or LCP formulation of benzimidazole drugs (2.5 µg/ml) for 24 h [82].

Recently, our group formulated benzimidazole drugs into 50 nm LCP nanoparticles. These drug-loaded LCP nanoparticles increased the solubility in PBS by 100-200% and significantly enhanced the apoptosis-induced anti-cancer efficacy in the treatment of B16F0 melanoma cells via generating more reactive oxygen species (ROS) and inhibiting Bcl-2 expression, as demonstrated in **Figure 4**. Very obviously, these drug-loaded LCP nanoparticles did not show any obvious toxicity and Bcl-2 inhibition in HEK293T healthy cells [82, 105].

7. Combination therapy with benzimidazole drugs




Figure 5. Improved chemotherapeutic outcomes by dual ligand targeting. **(A)** Tumor growth profile reflecting *in vivo* anti-tumor efficacy of OTS-ABZ-LCP, OTS-ABZ-LCP-P160 and OTS-ABZ-LCP-F100P160 intraperitoneally injected 3 times every two days in the B16F0-bearing mouse model compared to that of PBS injection; **(B)** PD-L1 expression by excised tumour cells; **(C)** CD4⁺ and **(D)** CD8⁺ immune cell populations in tumor tissues [131].

More frequently, benzimidazole drugs are combined with other chemotherapeutics, such as paclitaxel [10], trametinib [118], gemcitabine [119] and methoxyestradiol [120], to enhance the anti-cancer treatment efficacy. Flubendazole and albendazole at the low dosage were found to significantly potentiate the anti-proliferative effect of paclitaxel on colon cancers [10]. 2-Methoxyestradiol was the other microtubule-binding agent, exhibiting synergistic anti-cancer effect in combination with albendazole [120]. Mebendazole in combination with the methyl ethyl ketone (MEK) inhibitor, trametinib, demonstrated encouraging results for melanoma treatment by rapidly phosphorylating MEK and extracellular signal-regulated kinases (ERKs), and increasing apoptosis markers such as cleaved caspase-3 and poly (ADP-ribose) polymerase (PARP) [118]. The therapeutic effects of gemcitabine

was also promoted in combination with mebendazole [119] and parbendazole [121]. Interestingly, fenbendazole showed excellent anti-tumourigenic effect in combination with supplementary vitamins [122]. In addition to vitamins, fenbendazole in combination with rapamycin demonstrated synergistic anti-cancer effect against A549 cancer cells [123]. We also developed lipid-coated calcium phosphate (LCP) nanoparticles combining albendazole (ABZ) and a TOPK inhibitor, OTS964 for synergistic treatment of skin cancer. The dual-targeting capacity of the LCP nanoparticles to the programmed death ligand-1 (PD-L1) and folate receptor overexpressed on the surface of skin cancer cells enabled the combination therapy to completely suppress the skin tumour growth (**Figure 5A and B**) [124]. Furthermore, such combination treatment induced a certain level of local anti-cancer immunity by recruiting more CD4⁺ and CD8⁺ T cells into the tumor tissues (**Figure 5C and D**).

Moreover, benzimidazole drugs have also sensitized tumor cells to radiation therapy [93]. For example, as shown in **Figure 6**, mebendazole enhanced survival time and reduced colony formation of malignant meningioma [11], and also prevented radiation-induced conversion of triple-negative cancer cells into drug-resistant breast cancer-initiating cells and elevated the sensitivity of cancer cells to radiation [93]. Similarly, albendazole sensitized small cell lung cancer and metastatic melanoma cells to radiation therapy [125]. Albendazole not only induced DNA damage in those cells, but also arrested cell cycle at G2/M phase where cells are more sensitive to ionizing radiation. Therefore, combination of this antihelminthic drug with radiation therapy led to a synergistic cancer inhibition.




Figure 6. Increased survival rate (**A**), reduced tumour size obtained by IVIS imaging (**B**), and quantified average luminescence by IVIS (**C**) with the combination of mebendazole and radiation in KT21MG1-bearing mice [11].

8. Conclusions and future direction

Initially emerged as anti-helminth drugs, benzimidazole drugs have recently been repurposed as anti-cancer agents largely due to their safety in the long term applications. Benzimidazoles prevent cancer cell growth by inhibiting tubulin polymerization and disrupting mitotic spindles, leading to cell cycle arrest and inhibition of angiogenic factors such as HIF-1 α and VEGF. Moreover, these agents disable cell maintenance by elevating ROS generation and reducing ATP, thus suppressing many key enzymes and inducing apoptosis. A higher level of tubulin polymerization in rapidly dividing cells leads to a selective toxic effect of benzimidazoles on cancerous cells, leaving healthy cells intact. The higher sensitivity of cancer cells to ROS augmentation is the other factor for the selective activity of benzimidazoles. Such a selective effect, along with high efficacy in cancer treatment, represents benzimidazoles as a promising anti-cancer chemotherapeutics with minimum adverse side effects.

Benzimidazoles are also able to synergize other therapeutic approaches such as chemotherapy and radiation therapy. Some members of this family have also shown anti-cancer effect on drug-resistant cells and even cancer stem cells. Benzimidazoles not only enhance the efficacy of radiation therapy but also prevent cells from transformation to be resistant to the radiation treatment. On the other hand, benzimidazole treatment may cause tubulin mutation, and thus the combination with other therapeutics may be considered as the better choice.

Despite the extensive potentials of benzimidazole drugs for cancer treatment, their clinical application is still limited due to low water solubility and bioavailability. Nanoformulation of these drugs is promising for improving the solubility and bioavailability in addition to providing the opportunity of enhancing their circulation and tumor accumulation, targeted delivery and stimuli-responsive release. Until now, there are few studies that have investigated nanoformulations of these drugs for cancer therapy. Therefore, nanoformulation of benzimidazoles represents a promising future direction as it is still at the infant stage of research. Moreover, combination with other therapeutic modules, such as chemotherapeutics, radiation sensitizers, immune checkpoint inhibitors as well as target therapy in nanoformulations would synergize the therapeutic outcomes and bloom the repurpose applications of benzimidazole drugs in the fight with cancers in the near future.

Funding statement

This research was funded by Australian Research Council (ARC) Discovery Projects (DP190103486).

Acknowledgments

The authors acknowledge financial supports from Australian Research Council (ARC) Discovery Projects (DP190103486), and Australian Government Research Training Program Scholarship (RTP). The authors also appreciate facilities and the technical assistance of the Australian Microscopy & Microanalysis Research Facility at the Centre for Microscopy and Microanalysis (CMM), Australian National Fabrication Facility (Qld Node), The University of Queensland.

Conflict of interest

All the authors claim that the manuscript is completely original. The authors also declare no conflict of interest.

Author contributions

Conceptualization: Li Li, Zhiping Xu; Investigation: Fatemeh Movahedi; Writing–original draft: Fatemeh Movahedi; Writing–review & editing: Li Li, Zhiping Xu.

References

1. Senapati S, Mahanta AK, Kumar S, Maiti P: **Controlled drug delivery vehicles for cancer treatment and their performance**. In: *Signal Transduction and Targeted Therapy*. vol. 3: Springer Nature; 2018.
2. Lorusso D, Bria E, Costantini A, Di Maio M, Rosti G, Mancuso A: **Patients' perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey**. *European Journal of Cancer Care* 2017, **26**(2):e12618-e12618.
3. Zhang HZ, Damu GLV, Cai GX, Zhou CH: **Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole**. *European Journal of Medicinal Chemistry* 2013, **64**:329-344.
4. Nixon GL, McEntee L, Johnson A, Farrington N, Whalley S, Livermore J, Natal C, Washbourn G, Bibby J, Berry N *et al*: **Repurposing and reformulation of the antiparasitic agent flubendazole for treatment of cryptococcal meningoencephalitis, a neglected fungal disease**. *Antimicrobial Agents and Chemotherapy* 2018, **62**(4).
5. Bansal Y, Kaur M, Bansal G: **Antimicrobial Potential of Benzimidazole Derived Molecules**. *Mini-Reviews in Medicinal Chemistry* 2019, **19**(8):624-646.
6. Tonelli M, Simone M, Tasso B, Novelli F, Boido V, Sparatore F, Paglietti G, Pricl S, Giliberti G, Blois S *et al*: **Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives**. *Bioorganic and Medicinal Chemistry* 2010, **18**(8):2937-2953.
7. Lazer ES, Matteo MR, Possanza GJ: **Benzimidazole Derivatives with Atypical Antiinflammatory Activity**. *Journal of Medicinal Chemistry* 1987, **30**(4):726-729.
8. Ashall F: **Cancer cells and parasites: two of a kind**. In: *Trends in Biochemical Sciences*. vol. 11: Elsevier Current Trends; 1986: 518-520.
9. Lee YT, Tan YJ, Oon CE: **Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine**. *Acta Pharm Sin B* 2023, **13**(2):478-497.
10. Králová V, Hanušová V, Staňková P, Knoppová K, Čáňová K, Skálová L: **Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines**. *Anticancer Drugs* 2013, **24**(9):911-919.
11. Skibinski CG, Williamson T, Riggins GJ: **Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma**. *Journal of Neuro-Oncology* 2018, **140**(3):529-538.
12. Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Zavareh RB *et al*: **The antihelminthic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma**. *Blood* 2010, **115**(23):4824-4833.
13. Pourgholami MH, Lu Y, Morris DL: **Albendazole inhibits paclitaxel-resistant 1A9PTX22 ovarian cancer cells**. *Cancer Research* 2014, **66**(8 Supplement).
14. Sridhar Goud N, Kumar P, Dawn Bharath R: **Recent Developments of Target-Based Benzimidazole Derivatives as Potential Anticancer Agents**. In: *Heterocycles - Synthesis and Biological Activities [Working Title]*. edn.: IntechOpen; 2020.
15. Mukhtar E, Adhami VM, Mukhtar H: **Targeting microtubules by natural agents for cancer therapy**. In: *Molecular Cancer Therapeutics*. vol. 13: NIH Public Access; 2014: 275-284.
16. Cheong JE, Zaffagni M, Chung I, Xu Y, Wang Y, Jernigan FE, Zetter BR, Sun L: **Synthesis and anticancer activity of novel water soluble benzimidazole carbamates**. *European Journal of Medicinal Chemistry* 2018, **144**:372-385.
17. Carvalho KP, Gadelha APR: **Effects of three benzimidazoles on growth, general morphology and ultrastructure of *Tritrichomonas foetus***. *FEMS Microbiology Letters* 2007, **275**(2):292-300.
18. Horton RJ: **Benzimidazoles in a wormy world**. *Parasitology Today* 1990, **6**(4):106-106.

19. Maddison JE, Page SW, Church DB: **Small animal clinical pharmacology**.
20. Chai JY: **Praziquantel treatment in trematode and cestode infections: An update**. In: *Infection and Chemotherapy*. vol. 45: Korean Society of Infectious Diseases; 2013: 32-43.
21. Keiser J, Engels D, Büscher G, Utzinger J: **Triclabendazole for the treatment of fascioliasis and paragonimiasis**. In: *Expert Opinion on Investigational Drugs*. vol. 14: Taylor & Francis; 2005: 1513-1526.
22. **Benzimidazoles - Pharmacology - Veterinary Manual**. In.
23. Mottier L, Alvarez L, Ceballos L, Lanusse C: **Drug transport mechanisms in helminth parasites: Passive diffusion of benzimidazole anthelmintics**. *Experimental Parasitology* 2006, **113**(1):49-57.
24. **Encyclopedia of Parasitology: A-M - Horst Aspöck - Google Books**. In.
25. Dawson PJ, Gutteridge WE, Gull K: **A comparison of the interaction of anthelmintic benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode *Ascaridia galli***. *Biochemical Pharmacology* 1984, **33**(7):1069-1074.
26. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD: **Antiprotozoal activities of benzimidazoles and correlations with β - tubulin sequence**. *Antimicrobial Agents and Chemotherapy* 1994, **38**(9):2086-2090.
27. Morgan UM, Reynoldson JA, Thompson RCA: **Activities of several benzimidazoles and tubulin inhibitors against *Giardia* spp. in vitro**. *Antimicrobial Agents and Chemotherapy* 1993, **37**(2):328-331.
28. Edlind TD, Hang TL, Chakraborty PR: **Activity of the anthelmintic benzimidazoles against *Giardia lamblia* in vitro**. *J Infect Dis* 1990, **162**(6):1408-1411.
29. Seiler JP: **Toxicology and genetic effects of benzimidazole compounds**. *Mutation Research/Reviews in Genetic Toxicology* 1975, **32**(2):151-167.
30. Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, Fulda S *et al*: **Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen**. *Scientific Reports* 2015, **5**(1):1-9.
31. Ríos D, Restrepo JC: **Albendazole-induced liver injury: a case report**. *Colombia medica (Cali, Colombia)* 2013, **44**(2):118-120.
32. Watson M: **Benomyl (JMPR Evaluation 1995 Part II Toxicological and environmental) JMPR Evaluation 1995 Part II Toxicological and environmental** 1995, **2**.
33. Davis A, Dixon H, Pawlowski ZS: **Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2)**. *Bulletin of the World Health Organization* 1989, **67**(5):503-508.
34. Franchi C, Vico Bruno D, Teggi A: **Long-Term Evaluation of Patients with Hydatidosis Treated with Benzimidazole Carbamates**. *Clinical Infectious Diseases* 1999, **29**(2):304-309.
35. Page SW: **Antiparasitic drugs**. In: *Small Animal Clinical Pharmacology*. edn.: Elsevier Ltd; 2008: 198-260.
36. Cooper GM: **Microtubules**. 2000.
37. Dorosti Z, Yousefi M, Sharafi SM, Darani HY: **Mutual action of anticancer and antiparasitic drugs: are there any shared targets?** *Future Oncology* 2014, **10**(15):2529-2539.
38. Narasimhan PB, Akabas L, Tariq S, Huda N, Bennuru S, Sabzevari H, Hofmeister R, Nutman TB, Tolouei Semnani R: **Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion**. *PLoS Neglected Tropical Diseases* 2018, **12**(4).
39. Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A: **The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug**. *American journal of cancer research* 2018, **8**(2):317-331.
40. Maude RJ, Woodrow CJ, White LJ: **Artemisinin antimalarials: Preserving the "magic bullet"**. In: *Drug Development Research*. vol. 71: Wiley-Blackwell; 2010: 12-19.
41. Engel JA, Jones AJ, Avery VM, Sumanadasa SDM, Ng SS, Fairlie DP, Adams TS, Andrews KT: **Profiling the**

- anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.** *International Journal for Parasitology: Drugs and Drug Resistance* 2015, **5**(3):117-126.
42. Chen W, Mook RA, Premont RT, Wang J: **Niclosamide: Beyond an antihelminthic drug.** In: *Cellular Signalling*. vol. 41: Elsevier Inc.; 2018: 89-96.
43. Sharma N, Thomas S, Golden EB, Hofman FM, Chen TC, Petasis NA, Schönthal AH, Louie SG: **Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent.** *Cancer Letters* 2012, **326**(2):143-154.
44. Guzmán EA, Johnson JD, Linley PA, Gunasekera SE, Wright AE: **A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis.** *Investigational new drugs* 2011, **29**(5):777-785.
45. Hasanpourghadi M, Karthikeyan C, Pandurangan AK, Looi CY, Trivedi P, Kobayashi K, Tanaka K, Wong WF, Mustafa MR: **Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell.** *Journal of Experimental and Clinical Cancer Research* 2016, **35**(1):58-58.
46. Di Cesare E, Verrico A, Miele A, Giubettini M, Rovella P, Coluccia A, Famigliani V, La Regina G, Cundari E, Silvestri R *et al*: **Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules.** *Oncotarget* 2017, **8**(12):19738-19759.
47. Meissner M, Pinter A, Michailidou D, Hrgovic I, Kaprolat N, Stein M, Holtmeier W, Kaufmann R, Gille J: **Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms.** *Journal of Investigative Dermatology* 2008, **128**(8):2084-2091.
48. Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR: **VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis.** *Journal of Cell Communication and Signaling* 2016, **10**(4):347-354.
49. Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou P: **Microtubules regulate hypoxia-inducible factor-1 α protein trafficking and activity: Implications for taxane therapy.** *Journal of Biological Chemistry* 2012, **287**(15):11859-11869.
50. Sermeus A, Genin M, Maincent A, Fransolet M, Notte A, Leclere L, Riquier H, Arnould T, Michiels C: **Hypoxia-Induced Modulation of Apoptosis and BCL-2 Family Proteins in Different Cancer Cell Types.** *PLoS ONE* 2012, **7**(11):e47519-e47519.
51. Forrester SJ, Kikuchi DS, Hernandez MS, Xu Q, Griendling KK: **Reactive oxygen species in metabolic and inflammatory signaling.** In: *Circulation Research*. vol. 122: Lippincott Williams and Wilkins; 2018: 877-902.
52. Bhatti JS, Bhatti GK, Reddy PH: **Mitochondrial dysfunction and oxidative stress in metabolic disorders — A step towards mitochondria based therapeutic strategies.** In: *Biochimica et Biophysica Acta - Molecular Basis of Disease*. vol. 1863: Elsevier B.V.; 2017: 1066-1077.
53. Mrkvová Z, Uldrijan S, Pombinho A, Bartůňek P, Slaninová I: **Benzimidazoles downregulate MDM2 and MDMX and activate p53 in MDMX overexpressing tumor cells.** *Molecules* 2019, **24**(11).
54. Tejada P, Sanchez-Moreno M, Monteoliva M, Gomez-Banqueri H: **Inhibition of malate dehydrogenase enzymes by benzimidazole anthelmintics.** *Veterinary Parasitology* 1987, **24**(3-4):269-274.
55. Nguyen PTM, Baldeck JD, Olsson J, Marquis RE: **Antimicrobial actions of benzimidazoles against oral streptococci.** *Oral Microbiology and Immunology* 2005, **20**(2):93-100.
56. Barrowman MM, Marriner SE, Bogan JA: **The fumarate reductase system as a site of anthelmintic attack in Ascaris suum.** *Bioscience Reports* 1984, **4**(10):879-883.
57. Singla P, Luxami V, Paul K: **Benzimidazole-biologically attractive scaffold for protein kinase inhibitors.** In: *RSC Advances*. vol. 4: The Royal Society of Chemistry; 2014: 12422-12440.
58. Pereira GAN, Santos LH, Wang SC, Martins LC, Villela FS, Liao W, Dessoy MA, Dias LC, Andricopulo AD, Costa MAF

- et al*: **Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei**. *Future Medicinal Chemistry* 2019, **11**(13):1537-1551.
59. Castro LSEW, Kwiecinski MR, Ourique F, Parisotto EB, Grienevicius VMAS, Correia JFG, Wilhelm Filho D, Pedrosa RC: **Albendazole as a promising molecule for tumor control**. *Redox Biology* 2016, **10**:90-99.
60. Dogra N, Kumar A, Mukhopadhyay T: **Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways**. *Scientific Reports* 2018, **8**(1):1-15.
61. Gu M, Zhang Y, Zhou X, Ma H, Yao H, Ji F: **Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines**. *Oncology Letters* 2014, **8**(4):1739-1744.
62. Pinto LC, Soares BM, Pinheiro JdJV, Riggins GJ, Assumpção PP, Burbano RMR, Montenegro RC: **The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model**. *Toxicology in Vitro* 2015, **29**(8):2038-2044.
63. Xu D, Tian W, Jiang C, Huang Z, Zheng S: **The anthelmintic agent oxfendazole inhibits cell growth in non-small cell lung cancer by suppressing c-Src activation**. *Molecular Medicine Reports* 2019, **19**(4):2921-2926.
64. Lin S, Yang L, Yao Y, Xu L, Xiang Y, Zhao H, Wang L, Zuo Z, Huang X, Zhao C: **Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy**. *Journal of Experimental and Clinical Cancer Research* 2019, **38**(1):293-293.
65. Dai X, Wang L, Deivasigamni A, Looi CY, Karthikeyan C, Trivedi P, Chinnathambi A, Alharbi SA, Arfuso F, Dharmarajan A *et al*: **A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma**. *Oncotarget* 2017, **8**(8):12831-12842.
66. Chen Q, Li Y, Zhou X, Li R: **Oxibendazole inhibits prostate cancer cell growth**. *Oncology Letters* 2018, **15**(2):2218-2226.
67. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL: **In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole**. In: *Cancer Letters*. vol. 165; 2001: 43-49.
68. Sasaki J-i, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T: **The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells**. *Molecular cancer therapeutics* 2002, **1**(13):1201-1209.
69. Popović DJ, Lalošević D, Popović KJ, Čapo I, Popović JK, Miljković D: **Effect of mebendazole on fibrosarcoma in hamsters**. *Tropical Journal of Pharmaceutical Research* 2017, **16**(10):2445-2451.
70. Mukhopadhyay T, Sasaki J-i, Ramesh R, Roth JA: **Mebendazole Elicits a Potent Antitumor Effect on Human Cancer Cell Lines Both in Vitro and in Vivo**. *Clinical Cancer Research* 2002, **8**(9):2963-2969.
71. Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL: **Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model**. *Journal of Nanobiotechnology* 2015, **13**(1):25-25.
72. Florio R, Carradori S, Veschi S, Brocco D, Di Genni T, Cirilli R, Casulli A, Cama A, De Lellis L: **Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy**. *Pharmaceuticals (Basel)* 2021, **14**(4).
73. Abd El-Karim SS, Anwar MM, Zaki ER, Elseginy SA, Nofal ZM: **Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents**. *Future Medicinal Chemistry* 2018, **10**(2):157-181.
74. Karaaslan C, Bakar F, Goker H: **Antiproliferative activity of synthesized some new benzimidazole carboxamidines against MCF-7 breast carcinoma cells**. *Zeitschrift fur Naturforschung - Section C Journal of Biosciences* 2018, **73**(3-4):137-145.
75. Maji B, Kumar K, Kaulage M, Muniyappa K, Bhattacharya S: **Design and synthesis of new benzimidazole-carbazole conjugates for the stabilization of human telomeric DNA, telomerase inhibition,**

- and their selective action on cancer cells. *Journal of Medicinal Chemistry* 2014, **57**(16):6973-6988.
76. Liu J-F, Huang Y-L, Yang W-H, Chang C-S, Tang C-H: **1-Benzyl-2-Phenylbenzimidazole (BPB), a Benzimidazole Derivative, Induces Cell Apoptosis in Human Chondrosarcoma through Intrinsic and Extrinsic Pathways.** *International Journal of Molecular Sciences* 2012, **13**(12):16472-16488.
77. Yeong KY, Nor Azizi MIH, Berdigaliyev N, Chen WN, Lee WL, Shirazi AN, Parang K: **Sirtuin inhibition and anti-cancer activities of ethyl 2-benzimidazole-5-carboxylate derivatives.** *MedChemComm* 2019, **10**(12):2140-2145.
78. Paul K, Sharma A, Luxami V: **Synthesis and in vitro antitumor evaluation of primary amine substituted quinazoline linked benzimidazole.** *Bioorganic and Medicinal Chemistry Letters* 2014, **24**(2):624-629.
79. Rashid M, Husain A, Mishra R, Karim S, Khan S, Ahmad M, Al-wabel N, Husain A, Ahmad A, Khan SA: **Design and synthesis of benzimidazoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as a source of new anticancer agents.** *Arabian Journal of Chemistry* 2019, **12**(8):3202-3224.
80. Suk F-M, Liu C-L, Hsu M-H, Chuang Y-T, Wang JP, Liao Y-J: **Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.** *Scientific Reports* 2019, **9**(1):17259.
81. Spengler G, Kincses A, Rácz B, Varga B, Watanabe G, Saijo R, Sekiya H, Tamai E, Maki J, Molnár J *et al*: **Benzoxazole-based Zn(II) and Cu(II) Complexes Overcome Multidrug-resistance in Cancer.** *Anticancer Res* 2018, **38**(11):6181-6187.
82. Movahedi F, Gu W, Soares CP, Xu ZP: **Encapsulating Anti-Parasite Benzimidazole Drugs into Lipid-Coated Calcium Phosphate Nanoparticles to Efficiently Induce Skin Cancer Cell Apoptosis.** *Frontiers in Nanotechnology* 2021, **3**:44-44.
83. Parker AL, Kavallaris M, McCarroll JA: **Microtubules and their role in cellular stress in cancer.** *Frontiers in oncology* 2014, **4**:153-153.
84. Choi DG, Venkatesan J, Shim MS: **Selective anticancer therapy using pro-oxidant drug-loaded chitosan-fucoidan nanoparticles.** *International Journal of Molecular Sciences* 2019, **20**(13).
85. Wang M, Wu Y, Xu C, Zhao R, Huang Y, Zeng X, Chen T: **Design and Synthesis of 2-(5-Phenylindol-3-yl)benzimidazole Derivatives with Antiproliferative Effects towards Triple-Negative Breast Cancer Cells by Activation of ROS-Mediated Mitochondria Dysfunction.** *Chemistry – An Asian Journal* 2019, **14**(15):2648-2655.
86. Ullah A, Shah F, Khan I, Anwar M, Shah K, Muhammad MT, Ahmad F: **Unprecedented chemosensing behavior of novel tetra-substituted benzimidazole zinc(II) phthalocynine for selective detection of Bi³⁺ ion: Synthesis, characterization and ROS generation.** *Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy* 2018, **192**:188-193.
87. Williamson T, Mendes TB, Joe N, Cerutti JM, Riggins GJ: **Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer.** *Endocrine-Related Cancer* 2020, **27**(3):123-136.
88. Oh E, Kim Y-J, An H, Sung D, Cho T-M, Farrand L, Jang S, Seo JH, Kim JY: **Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.** *International Journal of Cancer* 2018, **143**(8):1978-1993.
89. Zhang B, Ling T, Zhaxi P, Cao Y, Qian L, Zhao D, Kang W, Zhang W, Wang L, Xu G *et al*: **Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression.** *Cancer Letters* 2019, **452**:23-30.
90. Wu Y, Li G, He D, Yang F, He G, He L, Zhang H, Deng Y, Fan M, Shen L *et al*: **Telomerase reverse transcriptase methylation predicts lymph node metastasis and prognosis in patients with gastric cancer.** *OncoTargets and Therapy* 2016, **9**:279-286.

91. Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovskaya A: **Cancer stem cells: The root of tumor recurrence and metastases**. In: *Seminars in Cancer Biology*. vol. 44: Academic Press; 2017: 10-24.
92. Ren Yuan B, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ: **Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme**. In: *Neuro-Oncology*. 2011; 13(19):974-982.
93. Zhang L, Bochkur Dratver M, Yazal T, Dong K, Nguyen A, Yu G, Dao A, Bochkur Dratver M, Duhachek-Muggy S, Bhat K *et al*: **Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer**. *International Journal of Radiation Oncology Biology Physics* 2019, **103**(1):195-207.
94. Khalilzadeh A, Wangoo KT, Morris DL, Pourgholami MH: **Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways**. *Biochemical pharmacology* 2007, **74**(3):407-414.
95. Chu SWL, Badar S, Morris DL, Pourgholami MH: **Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole**. *Anticancer research* 2009, **29**(10):3791-3796.
96. Carpenter RD, Andrei M, Lau EY, Lightstone FC, Liu R, Lam KS, Kurth MJ: **Highly potent, water soluble benzimidazole antagonist for activated $\alpha 4 \beta 1$ integrin**. *Journal of Medicinal Chemistry* 2007, **50**(23):5863-5867.
97. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE: **Kupffer cells in the liver**. *Compr Physiol* 2013, **3**(2):785-797.
98. Blanco E, Shen H, Ferrari M: **Principles of nanoparticle design for overcoming biological barriers to drug delivery**. In: *Nature Biotechnology*. vol. 33: Nature Publishing Group; 2015: 941-951.
99. Bilardo R, Traldi F, Vdovchenko A, Resmini M: **Influence of surface chemistry and morphology of nanoparticles on protein corona formation**. *Wiley Interdiscip Rev Nanomed Nanobiotechnol* 2022, **14**(4):e1788.
100. He C, Hu Y, Yin L, Tang C, Yin C: **Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles**. *Biomaterials* 2010, **31**(13):3657-3666.
101. Champion JA, Mitragotri S: **Role of target geometry in phagocytosis**. *Proc Natl Acad Sci U S A* 2006, **103**(13):4930-4934.
102. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP: **Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment**. *J Pers Med* 2021, **11**(6).
103. Matsumura Y, Maeda H: **A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs**. *Cancer Res* 1986, **46**(12 Pt 1):6387-6392.
104. Zhou W, Jia Y, Liu Y, Chen Y, Zhao P: **Tumor Microenvironment-Based Stimuli-Responsive Nanoparticles for Controlled Release of Drugs in Cancer Therapy**. *Pharmaceutics* 2022, **14**(11).
105. Movahedi F, Wu Y, Gu W, Xu ZP: **Nanostructuring a Widely Used Antiworm Drug into the Lipid-Coated Calcium Phosphate Matrix for Enhanced Skin Tumor Treatment**. *ACS Applied Bio Materials* 2020, **3**(7):4230-4238.
106. Fernández M, Javadi F, Chudasama V: **Advances in targeting the folate receptor in the treatment/imaging of cancers**. *Chem Sci* 2018, **9**(4):790-810.
107. Kefayat A, Hosseini M, Ghahremani F, Jolfaie NA, Rafienia M: **Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment**. *Journal of Nanobiotechnology* 2022, **20**(1):169.
108. Liang J, Li R, He Y, Ling C, Wang Q, Huang Y, Qin J, Lu W, Wang J: **A novel tumor-targeting treatment strategy uses energy restriction via co-delivery of albendazole and nanosilver**. *Nano Research* 2018, **11**(9):4507-4523.
109. Rathore A, Jain A, Gulbake A, Shilpi S, Khare P, Jain A, Jain SK: **Mannosylated liposomes bearing Amphotericin B**

- for effective management of visceral Leishmaniasis.** *Journal of Liposome Research* 2011, **21**(4):333-340.
110. Graves RA, Ledet GA, Nation CA, Prammar YV, Bostanian LA, Mandal TK: **Effect of squalane on mebendazole-loaded Compritol® nanoparticles.** *Journal of Biomaterials Science, Polymer Edition* 2015, **26**(13):868-880.
111. Manal A, El-Melegy N, Ghoneim S, Mohamed N, El-Dien N, Rizk M: **Silver Nano Particles Improve the Therapeutic Effect of Mebendazole Treatment during the Muscular Phase of Experimental Trichinellosis.** In: *Journal of American Science*. 2019.
112. Martín-de-Lucía I, Gonçalves SF, Leganés F, Fernández-Piñas F, Rosal R, Loureiro S: **Combined toxicity of graphite-diamond nanoparticles and thiabendazole to Daphnia magna.** *Science of the Total Environment* 2019, **688**:1145-1154.
113. Zhang XN, Zhang Q, Wen H, Wang GQ, Sun DJ: **Preparation of albendazole polybutyrcyanocrylate nanoparticles and study on its pharmaceutical properties and tissue distribution.** *Yaoxue Xuebao* 2003, **38**(6):462-466.
114. Aminpour S, Rafiei A, Jelowdar A, Kouchak M: **Evaluation of the Protoscolicidal Effects of Albendazole and Albendazole Loaded Solid Lipid Nanoparticles.** *Iranian journal of parasitology* 2019, **14**(1):127-135.
115. Farhadi M, Haniloo A, Rostamizadeh K, Faghihzadeh S: **Efficiency of flubendazole-loaded mPEG-PCL nanoparticles: A promising formulation against the protoscoleces and cysts of Echinococcus granulosus.** *Acta Trop* 2018, **187**:190-200.
116. Kang B-S, Choi J-S, Lee S-E, Lee J-K, Kim T-H, Jang WS, Tunsirikongkon A, Kim J-K, Park J-S: **Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles.** *Carbohydrate Polymers* 2017, **159**:39-47.
117. Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL: **Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.** *Journal of Nanobiotechnology* 2015, **13**(1):25.
118. Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF *et al*: **The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.** *Oncotarget* 2017, **8**(8):12576-12595.
119. Coyne CP: **Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.** *Journal of Cancer Research and Therapeutic Oncology* 2013, **2**(1).
120. Ehteda A, Galettis P, Pillai K, Morris DL: **Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice.** *BMC cancer* 2013, **13**:86-86.
121. Florio R, Veschi S, Di Giacomo V, Pagotto S, Carradori S, Verginelli F, Cirilli R, Casulli A, Grassadonia A, Tinari N *et al*: **The benzimidazole-based anthelmintic parbendazole: A repurposed drug candidate that synergizes with gemcitabine in pancreatic cancer.** *Cancers* 2019, **11**(12).
122. Gao P, Dang CV, Watson J: **Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins.** *Journal of the American Association for Laboratory Animal Science* 2008, **47**(6):37-40.
123. Shin HJ, Jo MJ, Jin IS, Park C-W, Kim J-S, Shin DH: **Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles.** *International Journal of Nanomedicine* 2021, **Volume 16**:4873-4889.
124. Movahedi F, Liu J, Sun B, Cao P, Sun L, Howard C, Gu W, Xu ZP: **PD-L1-Targeted Co-Delivery of Two Chemotherapeutics for Efficient Suppression of Skin Cancer Growth.** *Pharmaceutics* 2022, **14**(7).
125. Patel K, Doudican NA, Schiff PB, Orlow SJ: **Albendazole sensitizes cancer cells to ionizing radiation.** *Radiation oncology (London, England)* 2011, **6**:160-160.
126. Can Nn, Evik UA, Saglik BmN, Zkay Y, Atlı Z, Baysal M, Zkay mD, Can zrD: **Pharmacological and Toxicological**

- Screening of Novel Benzimidazole-Morpholine Derivatives as Dual-Acting Inhibitors.** *Molecules* 2017, **22**(8).
127. Weber P BGBDW: **The Effects of Triclabendazole on the Lung Fluke, Paragonimus Uterobilateralis in the Experimental Host Sigmodon Hispidus** - PubMed. In: *Trop Med Parasitol.* 1988: 39(34):322–324.-339(324):322–324.
128. Jaroonsesama N, Charoenlarp K, Cross JH: **Treatment of Opisthorchis Viverrini With Mebendazole** - PubMed. In: *Southeast Asian J Trop Med Public Health.* 1981: 595-597.
129. Talaie H, Emami H, Yadegarinia D, Nava-Ocampo AA, Massoud J, Azmoudeh M, Mas-Coma S: **Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.** *Clinical and Experimental Pharmacology and Physiology* 2004, **31**(11):777-782.
130. Marti OG, Stewart TB, Hale OM: **Comparative Efficacy of Fenbendazole, Dichlorvos, and Levamisole HCl against Gastrointestinal Nematodes of Pigs.** *The Journal of Parasitology* 1978, **64**(6):1028-1028.
131. Gasilina A, Premnauth G, Gurjar P, Biesiada J, Hegde S, Milewski D, Ma G, Kalin TV, Merino E, Meller J *et al*: **IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models.** *PLoS ONE* 2020, **15**(3):e0229801-e0229801.
132. De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Al Dimassi S, Atlas M, Boockvar J, Ruggieri R, Symons M: **Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors.** *Molecular Medicine* 2017, **23**:50-56.